Suppr超能文献

葡萄糖醛酸转移酶基因型与尼古丁代谢表型:功能性 UGT2B10 和 UGT2B17 多态性的重要性。

Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

机构信息

Molecular Epidemiology and Cancer Control Program, Penn State Cancer Institute, Department of Public Health Sciences, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA.

出版信息

Cancer Res. 2010 Oct 1;70(19):7543-52. doi: 10.1158/0008-5472.CAN-09-4582. Epub 2010 Sep 28.

Abstract

Glucuronidation is an important pathway in the metabolism of nicotine, with previous studies suggesting that ∼22% of urinary nicotine metabolites are in the form of glucuronidated compounds. Recent in vitro studies have suggested that the UDP-glucuronosyltransferases (UGT) 2B10 and 2B17 play major roles in nicotine glucuronidation with polymorphisms in both enzymes shown to significantly alter the levels of nicotine-glucuronide, cotinine-glucuronide, and trans-3'-hydroxycotinine (3HC)-glucuronide in human liver microsomes in vitro. In the present study, the relationship between the levels of urinary nicotine metabolites and functional polymorphisms in UGTs 2B10 and 2B17 was analyzed in urine specimens from 104 Caucasian smokers. Based on their percentage of total urinary nicotine metabolites, the levels of nicotine-glucuronide and cotinine-glucuronide were 42% (P < 0.0005) and 48% (P < 0.0001), respectively, lower in the urine from smokers exhibiting the UGT2B10 (*1/*2) genotype and 95% (P < 0.05) and 98% (P < 0.05), respectively, lower in the urine from smokers with the UGT2B10 (*2/*2) genotype compared with the urinary levels in smokers having the wild-type UGT2B10 (*1/*1) genotype. The level of 3HC-glucuronide was 42% (P < 0.001) lower in the urine from smokers exhibiting the homozygous UGT2B17 (*2/*2) deletion genotype compared with the levels in urine from wild-type UGT2B17 subjects. These data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine, cotinine, and 3HC and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion significantly reduce overall glucuronidation rates of nicotine and its major metabolites in smokers.

摘要

葡萄糖醛酸化是尼古丁代谢的重要途径,先前的研究表明,尿液中尼古丁代谢物的约 22%以葡萄糖醛酸结合物的形式存在。最近的体外研究表明,UDP-葡糖醛酸基转移酶 (UGT) 2B10 和 2B17 在尼古丁葡萄糖醛酸化中起主要作用,两种酶的遗传多态性显著改变了人肝微粒体中尼古丁-葡糖醛酸、可替宁-葡糖醛酸和反-3'-羟基可替宁(3HC)-葡糖醛酸的水平。在本研究中,分析了 104 名白种吸烟人群尿液中 UGT2B10 和 2B17 功能多态性与尿液中尼古丁代谢物水平之间的关系。根据其尿液中尼古丁代谢物总量的百分比,尼古丁葡萄糖醛酸和可替宁葡萄糖醛酸的水平分别降低了 42%(P < 0.0005)和 48%(P < 0.0001),在 UGT2B10 (*1/*2) 基因型的吸烟者尿液中,分别降低了 95%(P < 0.05)和 98%(P < 0.05),在 UGT2B10 (*2/*2) 基因型的吸烟者尿液中,与 UGT2B10 (*1/*1) 野生型基因型的吸烟者尿液水平相比,分别降低了 42%(P < 0.001)和 48%(P < 0.0001)。3HC-葡萄糖醛酸的水平在 UGT2B17 纯合缺失基因型 (*2/*2) 的吸烟者尿液中降低了 42%(P < 0.001),与 UGT2B17 野生型受试者的尿液水平相比。这些数据表明 UGTs 2B10 和 2B17 在尼古丁、可替宁和 3HC 的葡萄糖醛酸化中起重要作用,并表明 UGT2B10 密码子 67 SNP 和 UGT2B17 基因缺失显著降低了吸烟者尼古丁及其主要代谢物的总体葡萄糖醛酸化率。

相似文献

1
Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.
Cancer Res. 2010 Oct 1;70(19):7543-52. doi: 10.1158/0008-5472.CAN-09-4582. Epub 2010 Sep 28.
2
Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
Pharmacogenet Genomics. 2012 Mar;22(3):183-90. doi: 10.1097/FPC.0b013e32834ff3a5.
3
Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
PLoS One. 2013 Aug 2;8(8):e70938. doi: 10.1371/journal.pone.0070938. Print 2013.
4
UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1423-31. doi: 10.1158/1055-9965.EPI-09-0959. Epub 2010 May 25.
6
Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1175-1184. doi: 10.1158/1055-9965.EPI-15-1245. Epub 2016 May 9.
7
UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):94-104. doi: 10.1158/1055-9965.EPI-14-0804. Epub 2014 Oct 2.
9
The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
Pharmacogenet Genomics. 2013 Dec;23(12):706-16. doi: 10.1097/FPC.0000000000000011.
10
Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1093-1099. doi: 10.1158/1055-9965.EPI-16-0920. Epub 2017 Mar 6.

引用本文的文献

2
3
Biochemical and genetic biomarkers associated with nicotine dependence in Mexican smokers.
Pharmacol Res Perspect. 2023 Oct;11(5):e01142. doi: 10.1002/prp2.1142.
4
Diurnal variability of cortisol in the Pennsylvania adult smoking study: Exploration of association with nicotine intake.
Int J Psychophysiol. 2023 Apr;186:24-32. doi: 10.1016/j.ijpsycho.2023.02.001. Epub 2023 Feb 9.
6
Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD).
Chem Res Toxicol. 2023 Feb 20;36(2):177-187. doi: 10.1021/acs.chemrestox.2c00259. Epub 2023 Jan 10.
7
Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
Cancer Epidemiol Biomarkers Prev. 2023 Jan 9;32(1):54-65. doi: 10.1158/1055-9965.EPI-22-0868.
8
Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation.
Genet Res (Camb). 2022 Sep 28;2022:2917881. doi: 10.1155/2022/2917881. eCollection 2022.
9
CYP2C19 Plays a Major Role in the Hepatic -Oxidation of Cotinine.
Drug Metab Dispos. 2023 Jan;51(1):29-37. doi: 10.1124/dmd.121.000624. Epub 2022 Feb 23.
10
Biochemistry of nicotine metabolism and its relevance to lung cancer.
J Biol Chem. 2021 Jan-Jun;296:100722. doi: 10.1016/j.jbc.2021.100722. Epub 2021 Apr 29.

本文引用的文献

1
Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.
J Pharmacol Exp Ther. 2010 Jan;332(1):202-9. doi: 10.1124/jpet.109.159855. Epub 2009 Sep 28.
2
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
Clin Pharmacol Ther. 2009 Jun;85(6):635-43. doi: 10.1038/clpt.2009.19. Epub 2009 Mar 11.
3
Nicotine chemistry, metabolism, kinetics and biomarkers.
Handb Exp Pharmacol. 2009(192):29-60. doi: 10.1007/978-3-540-69248-5_2.
4
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.
J Neurogenet. 2009;23(3):252-61. doi: 10.1080/01677060802572887. Epub 2009 Jan 23.
5
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.
Pharmacol Biochem Behav. 2009 Mar;92(1):6-11. doi: 10.1016/j.pbb.2008.10.016. Epub 2008 Oct 31.
6
Tobacco addiction.
Lancet. 2008 Jun 14;371(9629):2027-38. doi: 10.1016/S0140-6736(08)60871-5.
7
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.
Clin Pharmacol Ther. 2008 Sep;84(3):320-5. doi: 10.1038/clpt.2008.57. Epub 2008 Apr 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验